
ZALTBOMMEL, Netherlands, Feb. 16 /Xinhua-PRNewswire/ -- The Dutch Golf Simulator is breaking through internationally. ProTee United, the producer of the simulator, introduced two new models at the largest golf fair in the world in Orlando, which took place earlier. (See also: http://www.pgamerchandiseshow.com ) "The response to our simulator was huge," Dennis van Drie, President of ProTee United, says. "Our goal was attracting new sales outlets and clients. This goal has been amply met. The international breakthrough of our simulator is now a fact." The latest generation of simulators manufactured by the Dutch producer are very advanced and realistic. Users have the possibility to play golf at any location they wish, using a virtual driving range or an 18 hole golf course, which includes bunkers, trees and water obstacles. Using the Simulator, everybody is able to play golf on every course in the world, so people can actually play at courses like Augusta, Pebble Beach or the K Club in Ireland, where the Ryder Cup will take place this year. "Our product has been tested by many professional golfers and famous long hitters. The longest drive was 385 yards, and reached a club speed of 156 miles per hour." What is the secret of the success of this Dutch Golf Simulator? "In Orlando, it appeared that we are distinctive regarding price, graphical performance (3D engine), modular structure (we use separate components, which are obtainable in any length, width, height and colour) and the quantity of sensor measuring systems." ProTee will launch a couple of add-ons this year: Vertical Sensors (which measure the Club head attack angle, the ball launch angle etc.) and special putting sensors. New applications The ProTee Golf Simulator is composed from different modules. The basis of the system is completed with two extra options, the `ball tracking sensor' and the `vertical club head attack angle sensor'. In addition, many, graphically improved, golf courses have been added. This offers the possibility to use the simulator for swing analysis at a club fitting. A combination of three sensor systems makes ProTee's simulator a unique product worldwide. NOTE TO EDITORS: At http://www.protee-united.com/downloads , you can find some visual material. For more information, please contact: Dennis van Drie President of ProTee United Tel: +31-0418-654-950 Email: dvdrie@protee-united.com Fax: +31-0418-654-959 SOURCE ProTee United B.V.

-- Prevention of Child Deaths Remains an Asian Priority -- Effective Surveillance is First Step to Eliminating Disease COLOMBO, Sri Lanka, Feb. 15 /Xinhua-PRNewswire/ -- The need for an urgent and sustained effort to document the burden of pneumococcal disease formed the core of discussions amongst leading scientists attending a WHO meeting today. With pneumococcal disease estimated to be responsible for up to one million child deaths each year(1) -- local efforts to measure the scale of the problem in Asia are essential in preventing unnecessary child deaths from Streptococcus pneumoniae -- a bacterium that causes pneumonia and meningitis. Serious pneumococcal infections occur throughout life, but young children (especially those under 2 years old) and the elderly are at the highest risk for severe pneumococcal disease. Furthermore, over 90% of pneumococcal pneumonia deaths in children occur in developing countries, and pneumococcal meningitis kills or disables over 40% of the children who get the disease. "Effective surveillance of pneumococcal disease and its serotypes is needed to accurately map the magnitude of the problem and help evaluate the impact of available vaccines", commented Dr Thomas Cherian, Co-ordinator a.i., EPI+, Vaccines and Biologicals at WHO. Pneumococcal disease is a major global health problem, and of concern in Asia. For example, at the Lady Ridgeway Hospital (LRH) for Children in Colombo, Sri Lanka -- one of the largest Children's hospitals in the region -- 794 pneumonia cases (32 deaths) and 295 meningitis cases (9 deaths) were reported in 2003(2). Pneumococcal surveillance, initiated in 2005, indicates that a sizable proportion of these cases could be due to infections by Streptococcus pneumoniae. Dr. Nihal Abeysinghe, the Chief Epidemiologist of the Ministry of Health, is pleased that Sri Lanka is a part of the South Asian Pneumococcal Alliance (SAPNA) and that pneumococcal surveillance conducted in Sri Lanka is based on sound methodology with high standards of quality control. He also emphasised the value and the importance of technical and financial assistance by WHO and GAVI's PneumoADIP in supporting and sustaining effective pneumococcal surveillance activities in Sri Lanka. Dr. Sarath de Silva, the Consultant Paediatrician at the LRH said that the improved Microbiology Laboratory support now provides clinicians with the opportunity to identify pneumococci as a leading cause of meningitis and pneumonia in children. In 2005, Streptococcus pneumoniae were isolated from specimens from 3 meningitis patients and 9 pneumonia patients. Dr. Kumudu Karunarathne, the Consultant Microbiologist, also at the LRH, commented that a high level of resistant pneumococci to commonly used antibiotics was a very significant finding in 2005. The fact that over 90% of the Streptococcus pneumoniae isolates are resistant to penicillin is of greatest concern, and all clinicians in the country should be aware of this fact. Fortunately, new vaccines to prevent deadly pneumococcal infections are now available and widely used in many countries in North America and Europe. As Dr. Katharine O'Brien, Deputy Director for Surveillance and Research at GAVI's PneumoADIP explained: "with systematic surveillance in place and a coordinated effort to introduce pneumococcal vaccines we could save millions of children's lives and make a significant move towards meeting a key UN Millennium Development Goal of reducing child mortality by two thirds by 2015". The Pneumococcal Surveillance Investigators meeting was sponsored by the World Health Organisation and GAVI's PneumoADIP(3) and brought together experts from a number of Asian countries including Bangladesh, India, Indonesia, Republic of Korea, Mongolia, Nepal, Sri Lanka, Thailand and Viet Nam. The importance placed on this meeting reflects the global community's increasing focus on pneumococcal disease, and the urgent need for a global solution. Only last week BBC World aired the second in a landmark series of programmes looking at pneumococcal disease and life-saving vaccines. The documentary took a close look at the burden of pneumococcal disease in India and Nepal, and the effort required to introduce a vaccine in developing countries. Notes to Editors Pneumococcal Disease Pneumococcal disease is an infection caused by Streptococcus pneumoniae. When these bacteria invade the lungs, they cause the most common kind of bacterial pneumonia and can then invade the bloodstream (bacteremia) and/or the tissues and fluids surrounding the brain and spinal cord (meningitis). According to WHO, pneumococcal pneumonia and meningitis are responsible for 800,000 to 1 million child deaths each year and more than 90 percent of pneumococcal pneumonia deaths in children occur in developing countries. Furthermore, approximately 500,000 children die each year from diarrhoeal disease caused by rotavirus, and another 2 million are hospitalized. Since rotavirus diarrhoea is a global infection, nearly every child in the world will suffer an episode of diarrhoea caused by rotavirus before 5 years of age. South Asian Pneumococcal Alliance (SAPNA) Sri Lanka became a member of the SAPNA in 2003 and started Laboratory based surveillance of pneumococcal infections in 2005 at the Lady Ridgeway Hospital for Children in Colombo. The Epidemiology Unit of the Ministry of Health coordinates the surveillance activities. It plans to expand surveillance activities to cover the whole Colombo district. World Health Organisation (WHO) The World Health Organization is the United Nations specialized agency for health. It was established on 7 April 1948. WHO's objective, as set out in its Constitution, is the attainment by all peoples of the highest possible level of health. Health is defined in WHO's Constitution as a state of complete physical, mental and social well-being and not merely the absence of disease or infirmity. Pneumococcal Vaccines Accelerated Development and Introduction Plan (PneumoADIP) The goal of PneumoADIP is to shorten the time between the use of a new vaccine in industrialized countries and its introduction in developing countries by reducing demand uncertainty and achieving an affordable, sustainable supply of vaccines. This novel approach is funded by the Global Alliance for Vaccines and Immunization (GAVI) through its partner the Vaccine Fund. PneumoADIP is located at the Johns Hopkins Bloomberg School of Public Health. The mission of PneumoADIP is to improve child survival and health by accelerating the evaluation of and access to new life saving pneumococcal vaccines for the world's children. For more information, please visit: http://www.preventpneumo.org . GAVI Alliance The Global Alliance for Vaccines and Immunization (now the GAVI Alliance) was launched in 2000 to increase immunization rates and reverse widening global disparities in access to vaccines. Governments in industrialized and developing countries, UNICEF, WHO, the World Bank, non-governmental organizations, foundations, vaccine manufacturers, and public health and research institutions work together as partners in the Alliance, to achieve common immunization goals, in the recognition that only through a strong and united effort can much higher levels of support for global immunization be generated. Funds channeled through GAVI's financing arm, The GAVI Fund (formerly The Vaccine Fund), are used to help strengthen health and immunization services, accelerate access to selected vaccines and new vaccine technologies -- especially vaccines that are new or under-used, and improve injection safety. In addition to substantial funding from the Bill & Melinda Gates Foundation, The Vaccine Fund has been financed by ten governments to date-Canada, Denmark, France, Ireland, Luxembourg, the Netherlands, Norway, Sweden, the United Kingdom, and the United States- as well as the European Union and private contributors. (1) World Health Organization. Pneumococcal vaccines. The Weekly Epidemiol Record 2003;14:110-9 (2) Annual Health Bulletin, LRH, 2003 (3) Pneumococcal Vaccines Accelerated Development and Introduction Plan (PneumoADIP) based at Johns Hopkins Bloomberg School of Public Health, USA For more information, please contact: Hans Kvist, Director, Communications, GAVI's PneumoADIP Tel: +1-410-736-8243 Email: hkvist@jhsph.edu Selina Haylock, Consultant, Ruder Finn Communications Tel: +44-776-882-3989 Email: shaylock@ruderfinn.co.uk Dr. Ranjith Batuwanthudawe, Principal Investigator, SAPNA Sri Lanka Project, Epidemiology Unit, Ministry of Health Tel: +94-112-695112 Email: chepid@sltnet.lk SOURCE GAVI's PneumoADIP

BARCELONA, Spain, Feb. 15 /Xinhua-PRNewswire/ -- SEVEN today announced that it has sold over 1 million licenses of its push email software of which approximately 75% are enterprise licenses and 25% are individual prosumer and consumer licenses. Over 80 mobile operators and service providers have selected SEVEN as their white-label push email solution. SEVEN's customers include some of the largest mobile operators in the world including Cingular offering XpressMail; KDDI offering Keitai Office; and Telefonica offering Mail Movistar -- all powered by SEVEN's push email software. SEVEN is the second largest provider of mobile email after market-leader Research in Motion as measured by the following leadership attributes: All information provided in the following table was sourced from the noted company's website as of February 14, 2006 as detailed in the footnotes. RIM SEVEN Intellisync Visto Good Mobile Operator Customers 150(1) 80(2) 19(3) 16(4) 2(5) Devices Supported 21+10(6) 120(7) 50(8) 75(9) 16(10) Device OS Support Proprietary 5 Brew; 4(11) 4(12) 3(13) Java; Brew; Symbian, Palm, Palm, Palm, Palm, Windows, Symbian, Symbian Windows Symbian Windows Windows Mobile, 5.0 5.0 Java Email Systems Supported 5 5 4(14) 4(15) 1(16) Exchange, Exchange, Exchange,Exchange,Exchange Domino, Domino, Domino, Domino, Groupwise, Groupwise,POP3, POP3, POP3, POP3, IMAP IMAP IMAP IMAP Ranking #1 #2 #3 #4 #5 One Million Licenses Sold -- Only One Indicator of Growth Surpassing sales of over 1M licenses is only one indication of SEVEN's growth rate as many of our customers buy licenses as they are "consumed" and not in advance -- at a pace that varies by market and by how long the SEVEN-powered service has been in market. In Japan, SEVEN has seen substantial growth in large-scale enterprise adoption and, for example, is currently deploying two large deployments of 10,000 and 8,000 licenses respectively. These are "pay as consumed" contracts and are additive to SEVEN's total license base. SEVEN believes the total market for push email will reach over one quarter billion subscribers within five years as push email becomes widely available as a standard feature across all mobile handsets. Customer Expansion to 80 Operators Includes High-Growth Markets SEVEN also has seen phenomenal growth in many high-growth markets such as India, the Middle East and South America. In India, SEVEN works with IDEA and Hutchison and has recently signed deals with two regional operators that are yet announced. In the Middle East, SEVEN works with MTC Vodafone Group, Wataniya, Batelco and Etisalat Group. In South America, SEVEN works with Telefonica across 14 properties and 15 countries. "SEVEN has been heads-down developing innovative technology to grow mobile email adoption. We want mobile email to work on every phone without hassle and major expense -- whether you are an enterprise or consumer," said Kent Thexton, President and CEO of SEVEN. "It is gratifying to see our progress against that goal -- while the market is still early in realizing its potential, we have built a solid foundation based on innovation that will cement our leadership position in the long term." NOTE: SEVEN is a registered trademark of Seven Networks, Inc. Out of the Office, System SEVEN, SEVEN Personal Edition, SEVEN Enterprise Edition, and SEVEN Server Edition are also trademarks or service marks of Seven Networks, Inc. All other trademarks or tradenames are those of their respective owners. 1) 3GSM World Congress February 14 2006; Presentation Title: Service Architecture to Drive Productivity; Speaker: Jim Balsillie, Chairman & Co-Chief Executive Officer, Research in Motion 2) http://www.seven.com/get_it/ 3) http://www.intellisync.com/pages/Customers/Mobile-Carriers/ 4) http://www.visto.com/partners/wireless.html 5) http://www.good.com/index.php/how_to_buy.html 6) http://www.rim.com/products/handhelds/index.shtml (21 Blackberry devices, 10 from other manufactures / Blackberry Connect) 7) http://www.seven.com/products/devices/index.html 8) http://www.intellisync.com (This is an estimated number based on the data gathered from different sources on the web site) 9) http://www.visto.com/news/press_kit.html (Fact Sheet) 10) http://www.good.com/index.php/products-software.html 11) www.intellisync.com/pages/products/email-accelerator 12) http://www.visto.com (About) 13) http://www.good.com/index.php/products-software.html 14) www.intellisync.com/pages/products/email-accelerator 15) http://www.avisto.com (About) 16) http://www.good.com/index.php/products-software.html For more information, please contact: Kate O'Sullivan Tel: +1-415-307-3148 Email: kate.osullivan@seven.com Arlinda Sipila Tel: +358-40-528-8651 Email: arlinda.sipila@seven.com SOURCE SEVEN

Approval Will Accelerate Enhancements to Australian Airspace
RENTON, Wash., Feb. 15 /Xinhua-PRNewswire/ -- Australia's Civil Aviation Safety Authority [CASA] has granted an Instrument Flight Procedure Design Certificate to Naverus, Inc., authorizing them to design and maintain Required Navigation [RNP RNAV] approach and departure procedures for the Australian airspace. The certification -- the first granted to an entity not affiliated with the government, and the only certification permitting the design of RNP-AR (Authorization Required) procedures -- will accelerate the deployment of performance-based navigation procedures, and enhance the safety as well as the efficiency of airlines serving airports in Australia. Bruce Gemmell, the Deputy Chief Executive and Chief Operating Officer of CASA, certified Naverus under Part 173 of the Civil Aviation Safety Regulations 1998. The certification follows a rigorous review of Naverus' operations, and consultation with Transport Canada, the FAA and the CAA of New Zealand about the safety aspects of the Naverus design criteria. The review included an independent, on-site audit of the Naverus design offices in Seattle, WA by CASA's Sophie Joshua and Paul Taylor. The CASA team inspected the processes and quality management plan that Naverus has developed through its design of over 250 RNP approach, departure and enroute procedures, including procedures designed for Australian and New Zealand airports. Gemmell noted in his decision that the Naverus design criteria "provide substantially increased safety over procedures designed using conventional criteria of the kind found in ICAO Doc. 8168 (PANS-OPS)" and, while consistent with the FAA and proposed ICAO criteria for RNP, "incorporates several features which permit additional safety and operational benefits" beyond those criteria. Dan Gerrity, Naverus' Chief Executive Officer, appreciated the rigor of CASA's review. "CASA has set the bar very high for this certification, as it should," observed Gerrity. "Australia's process gives other regulators around the world a strong model to follow as our industry moves to capture the benefits of performance-based navigation using RNP." CASA has also approved the appointment as chief designer of Naverus' Michael Ryan and Mark Brower, who lead the team of design engineers, performance engineers, and navigation data experts who to-date have designed and released hundreds of performance-based navigation procedures to multiple criteria for operators worldwide. The approval by CASA for Australia is the second granted to Naverus by a major regulatory agency. In 2004, Transport Canada granted Naverus a delegation to design, publish and maintain RNP RNAV procedures for Canada, under an exemption to that agency's CAR 803.02. Transport Canada renewed that grant in July, 2005. About Naverus Naverus is the leader in performance-based navigation solutions to airlines and airports worldwide. Naverus has developed and deployed over 250 RNP RNAV procedures for both Boeing and Airbus aircraft. Customers include JetBlue, Air New Zealand, Qantas and WestJet. The Seattle company was founded in 2003 by the industry's most experienced performance-based navigation experts. Based in Renton, WA, the company is a privately-held corporation. Investors include JGE Capital Management, other private equity groups and individuals. For more information, please visit http://www.naverus.com or call Naverus at 1-425-282-5250. About CASA The Civil Aviation Safety Authority (CASA) was established on 6 July 1995 as an independent statutory authority. CASA's primary function is to conduct the safety regulation of civil air operations in Australia and the operation of Australian aircraft overseas. The Civil Aviation Act and CAR 1988 empower CASA to issue Civil Aviation Orders on detailed matters of regulation. The Chief Executive Officer manages CASA, and is responsible to the Minister for Transport and Regional Services. For more information, please contact: Stew Chapin, Naverus Marketing Tel: +1-425-282-5267 Email: schapin@naverus.com SOURCE Naverus, Inc.

Development Initiatives for Creative and Business Consumers
STAMFORD, Conn. and STOCKHOLM, Sweden, Feb. 15 /Xinhua-PRNewswire/ -- Esselte, a leading global office supplies company, has announced a strategic partnership with the Swedish company PrintDreams. PrintDreams developed the RMPT(TM) Lite (Random Movement Print Technology) used in the newest product introduction from Xyron, part of Esselte's Creative Division. The Xyron(R) Design Runner(TM), a first-of-its-kind, cordless, hand-held, portable digital printer, was introduced in October 2005 and represents the first commercial application for RMPT Lite since its inception in 2003. The Esselte-PrintDreams partnership includes a minority equity position for Esselte in PrintDreams as well as a license agreement for the RMPT Full technology, which will be used in the development of innovative new products for Xyron and Esselte's office supply brands, Pendaflex(R) and Leitz(R). Financial terms of the partnership were not released. "This collaboration with PrintDreams is an extension of Esselte's commitment to identifying and securing innovative, ground-breaking technologies," commented Gary Brooks, president and CEO of Esselte. "With each new product introduction -- for our office, home office, craft, hobby, art and education markets -- we look to simplify complicated, cumbersome processes and make the consumer more productive. With go-forward partners like PrintDreams we are sure to reach new heights in these areas." The partnership will extend and expand upon the successful introduction of the Xyron Design Runner. This revolutionary portable printer is the first and only print device on the market that allows users to add printed elements to virtually any project, without wires, computer connections or an electric power source. The battery-operated Xyron Design Runner can print on nearly any substrate as well -- paper, fabric, ribbon, clay, and myriad other surfaces -- and uses a series of proprietary Design Discs that offer image, WordArt, texture and alphabet options. "Our vision at PrintDreams' is to establish a global de facto standard for truly portable printer devices," stated Alex Breton, chairman and CEO of PrintDreams. "RMPT technology is the foundation that will allow us to do just that. And with partners like Esselte we are sure to expand on the success of the Xyron Design Runner and provide real-time, portable printing solutions to consumers in a variety of markets." Esselte expects to introduce new and innovative digital printing products incorporating the RMPT Full technology beginning in late 2006 and early 2007. About PrintDreams PrintDreams is a Swedish high technology company that develops, markets and sells license rights for innovative technical solutions, primarily for the printer industry. The company has developed among others, RMPT(TM), which allows the manufacturing of truly portable printer devices suitable for mobile applications. Another advantage of RMPT (Random Movement Printing technology) is that it is highly flexible; allowing printing on almost any type, size or format of surface. Additionally it is very cost effective because the hundreds of mechanical parts common in traditional printers are replaced by an intelligent software-based control system. PrintDreams has also developed the world's foremost accurate optical navigation sensor called OptoNav(TM). This sensor has applications in more advanced printer products that the company is currently developing together with its partners. To get to know more about the company and its technologies please visit http://www.printdreams.com . About Esselte Esselte, with executive offices in Stamford, Conn., USA, is a leading global office supplies manufacturer with annual sales of approximately USD 1 billion, subsidiaries in 33 countries and approximately 5,000 employees worldwide. The company develops innovative solutions that simplify the modern home and workplace. Esselte sells more than 20,000 different office products in over 120 countries; its principal brands include Esselte, Leitz, Oxford(R), Pendaflex and Xyron. More information about Esselte can be found by visiting http://www.esselte.com . For more information, please contact: Amy Romano Tel: +1-480-607-6333 Email: a.romano@xyron.com SOURCE Esselte; PrintDreams

Further strengthens Group's market leadership in China
CHENGDU, China, Feb. 15 /Xinhua-PRNewswire/ -- InterContinental Hotels Group, the world's largest hotel group by number of rooms, today signed a landmark deal with Chengdu International Exhibition & Convention Group to manage six hotels in Chengdu and Jiuzhaigou in China's Sichuan province. This deal significant enhances the group's market dominance in China. The six hotels -- two InterContinental properties, three Holiday Inn properties and one Express by Holiday Inn -- comprise a total of more than 4,500 rooms. This landmark signing in Sichuan, China's second most populous province with over 90 million residents, marks a significant addition to InterContinental Hotels Group's already strong portfolio of about 50 hotels in Greater China. It puts the Group in a strong position to reach its target of having 125 hotels open in China by 2008. Chengdu, the strategically-located capital of Sichuan province, is both an emerging powerhouse and a popular tourism destination. It is a fast-developing city that has been named as one of the most livable cities China in and is one of the top-ranked cities for tourism and economic potential. The Jiuzhaigou Scenic Area, a 45-minute flight from Chengdu, is known for its pristine beauty, with emerald lakes, layered waterfalls, colourful forests, snow peaks and Tibetan folk villages. The area is listed as a UNESCO (United Nations Educational, Scientific and Cultural Organization) World Natural Heritage site. Andrew Cosslett, Chief Executive, IHG, who was in Chengdu for the signing, said: "This is the biggest single deal IHG has done in China, a country that lies at the heart of our growth strategy. Our brands have a strong foothold in Asia Pacific and Holiday Inn was one of the first international hotel brands to establish a presence there in 1984. This deal marks a major milestone as we move towards meeting our aggressive growth plans and we remain fully committed to maintaining our position as the leading hotel company in China." Edmond Ip, InterContinental Hotels Group's chief operating officer for North Asia, said: "This latest deal is concrete proof that InterContinental Hotels Group is indeed the hotel partner of choice. Our growing portfolio clearly demonstrates that our partners recognise the value of our award-winning brands and have complete confidence in our ability to deliver memorable guest experiences coupled with exceptional business performance." "We are pleased to cooperate with an experienced, international hotel operator like the InterContinental Hotels Group on this significant project. Our partnership with InterContinental Hotels Group combines their world-recognized hotel brands and established operating systems with our local market knowledge and property portfolio. We believe that this cooperation will also contribute to bringing Chengdu and Western China into sharper focus with the international business community," commented Deng Hong, Chairman of Chengdu Exhibition & Convention Group. The scheduled openings will comprise the following hotels: In Chengdu City, as part of the RMB 5 billion (US$620 million) New Century City international convention and exhibition centre, incorporating shopping, entertainment, offices, residences and a golf course: InterContinental Century City Chengdu, an upscale business hotel that will combine the latest communication and business technologies, high-end food and beverage options and conference facilities. Scheduled to open in 2007. The two Holiday Inn hotels at the Chengdu Century City New Convention & Exhibition Center are mid-scale hotels offering quality accommodation and business support services, specifically designed to host convention delegates. Scheduled to open in 2006. At the Jiuzhaigou Scenic Area, as part of Jiuzhai Paradise, hailed as the `Davos of China': InterContinental Resort Jiuzhai Paradise, an upscale hotel with eight F&B outlets and extensive conference and recreational facilities. Scheduled to open in 2006. Holiday Inn Jiuzhai Jarpo, a mid-scale hotel business services and spa facilities. Scheduled to open in 2006. Express by Holiday Inn Jiuzhai Jarpo, a convenience-sector hotel scheduled to open in 2007. Chengdu International Exhibition & Convention Group has interests in exhibitions and conventions, hotels, travel agencies and real estate. The Group commands more than 70% market share for exhibitions and conventions in Chengdu and had total revenues of RMB2.2 billion (US$265 million) in 2005. The first stage of the New Century City project in Chengdu is scheduled for completion by end of 2006. Note to Editors InterContinental Hotels Group PLC of the United Kingdom [LON: IHG, NYSE: IHG (ADRs)] is the world's largest hotel group by number of rooms. InterContinental Hotels Group owns, manages, leases or franchises, through various subsidiaries, almost 3,600 hotels and 539,000 guest rooms in nearly 100 countries and territories around the world. The Group owns a portfolio of well recognised and respected hotel brands including InterContinental(R) Hotels & Resorts, Crowne Plaza(R) Hotels & Resorts, Holiday Inn(R) Hotels and Resorts, Holiday Inn Express(R), Staybridge Suites(R), Candlewood Suites(R) and Hotel IndigoTM, and also manages the world's largest hotel loyalty programme, Priority Club(R) Rewards. Asia Pacific is the fastest growing region for InterContinental Hotels Group worldwide. The Group's portfolio in this region includes more than 160 hotels and over 44,000 guest rooms under the InterContinental(R) Hotels & Resorts, Crowne Plaza(R) Hotels & Resorts, Holiday Inn(R) Hotels and Resorts, and Express by Holiday Inn(R) brands. InterContinental Hotels Group offers information and online reservations for all its hotel brands at http://www.ichotelsgroup.com and information for the Priority Club Rewards programme at http://www.priorityclub.com . For the latest news from InterContinental Hotels Group, visit our online Press Office at http://www.ihgplc.com/media . For further press information and photos, please contact: Sharona Tao Brand Public Relations & Communications Manager, Greater China InterContinental Hotels Group Tel: +86-21-2893-3309 Fax: +86-21-2893-3399 Email: sharona.tao@ichotelsgroup.com SOURCE InterContinental Hotels Group

SHANGHAI, China, Feb. 15 /Xinhua-PRNewswire/ -- Shanghai Jinshan District Government announces that the first Petrochem Museum in China, Shanghai Petrochem Science and Technology Museum, formally opened recently in Jinshan District, Shanghai. That brings the total of specialized Science and Technology Museums in Shanghai to 17. Shanghai Petrochem Science and Technology Museum covers an area of 1,500 square meters, built under the joint investment of Shanghai Science and Technology Committee and SINOPEC Shanghai Petrochemical Co., Ltd. (SPC) and based on the original SPC Exhibition Hall. By adding more exhibitions and through using modern technology, the original SPC Exhibition Hall was transformed into the Shanghai Petrochem Science and Technology Museum. About Jinshan District Jinshan, one of the 19 districts (counties) of Shanghai, is located in the southwest of the city, north of the Hangzhou Bay and west of Zhejiang Province. It is situated at the hub of the economic region linking Shanghai, Hangzhou and Ningbo, and is inside the geographic ring of the Yangtze River Delta that is only a two hours drive away. Jinshan District has a total land area of 586 square kilometers (about 226 square miles), equivalent to that of Singapore, and a population of 550,000. It has rich natural and cultural heritages, including beautiful beach lines, famous traditional peasant paintings, black ceramic arts and crafts, and a world-renowned petrochemical base. For more information, please contact: Wang Ren of Shanghai Jinshan District Government Tel: +86-21-5792-1325 Fax: +86-21-5792-1100 Email: jsqzhk@sohu.com SOURCE General Office of the People's Government of Jinshan

BARCELONA, Spain, Feb. 14 /Xinhua-PRNewswire/ -- Today at the 3GSM World Congress, SEVEN announced the availability of its Workgroup Edition software extending the benefits of push-email to small businesses and departments within enterprises. SEVEN Workgroup Edition provides up to 25 users access to email, calendar, attachments and contacts on a wide range of mobile devices. Installation of the software typically takes less than 15 minutes and involves a simple download to a single computer connected to a corporate network -- no IT expertise is required. SEVEN's Workgroup Edition software was designed with the highest enterprise-class security: all the data associated with SEVEN's push-email client is secured by end-to-end 128-bit AES encryption and SEVEN's software comes rich with features such as remote data removal if a device is lost. SEVEN Workgroup Edition enables mobile access to email that originates in Microsoft Outlook, Lotus Domino, POP3-and IMAP-4 compliant email servers and allows users to access more than one email account (e.g. personal and work email accounts) through the same software at no additional charge. SEVEN Workgroup Edition is currently being deployed and offered through mobile operators and resellers worldwide. Mobile operators already offering SEVEN's Workgroup Edition include StarHub in Singapore offering StarHub Duality, Telemar in Brazil offering E-Mail Movel, and Pannon in Hungary offering Pannon E-Phone. In some markets, it is also offered as Ericsson Mobile Organizer from Ericsson. The cost to use SEVEN Workgroup Edition will vary from market to market, but as a general guideline it is typically offered for below 10 Euros per month per subscriber making it a very affordable productivity tool for businesses of all sizes. For a complete list of the 80 operators offering SEVEN software and their associated service fees, please visit http://www.seven.com/get_it and for companies and individuals interested in requesting a free trial, please visit: http://www.seven.com/get_it/info_request_form.html . * SEVEN is a registered trademark of Seven Networks, Inc. Out of the Office, System SEVEN, SEVEN Personal Edition, SEVEN Enterprise Edition, and SEVEN Server Edition are also trademarks or service marks of Seven Networks, Inc. All other trademarks or tradenames are those of their respective owners. North America & Japan Kate O'Sullivan Tel: +1-415-307-3148 Email: kate.osullivan@seven.com EMEA & APAC Arlinda Sipila Tel: +358-40-528-8651 Email: arlinda.sipila@seven SOURCE SEVEN

SHANGHAI, China, Feb. 14 /Xinhua-PRNewswire/ -- Xinhua Finance (TSE Mothers: 9399; OTC ADR: XHFNY), China's unchallenged leader in financial information and media, today reported net income of US$10.3 million for the full year 2005 under International Financial Reporting Standards ("IFRS"). Net income was significantly ahead of the full year forecast, which was revised upward in December 2005 to US$9.0 million. The company has continued to see significant growth across its global service lines. The record financial results for the full year are further evidence that management's focused strategy for profitable growth is driving shareholder value and that Xinhua Finance is well-positioned to capitalize on its promising business prospects in China and worldwide. Total revenue for the full year ended December 31, 2005 was US$110.0 million, an 84% increase over the full year 2004, surpassing the forecast of US$105.7 million by US$4.3 million or 4%. EBITDA, an important international measure of high growth companies such as Xinhua Finance, was US$21.2 million, a 364% increase from prior year EBITDA of US$4.6 million, beating the US$16.7 million forecast by 27%. Fredy Bush, CEO of Xinhua Finance, commented, "We are proud to have surpassed our full year revenue and EBITDA targets to deliver net income significantly ahead of expectations. Fiscal 2005 was a landmark year for Xinhua Finance, both financially and operationally. Continued strong demand for our China products as well as positive developments in China's regulatory environment drove growth across all of our business lines. We have seamlessly integrated our recent acquisitions into the group, and they already are strengthening our product portfolio and contributing to bottom line profit." "Looking forward to 2006, we expect to continue to advance our strategy to extend our distribution capabilities in China and penetrate the financial media sector. Our core businesses continue to grow. By improving the quality and depth of our proprietary content, we are creating additional leverage to develop these financial media distribution channels and diversify into new and lucrative revenue streams." CFO Gordon Lau added, "Xinhua Finance achieved record financial performance in fiscal 2005. Revenue, EBITDA and net income were at all time highs, a direct result of our disciplined approach to expand our margins and drive operational efficiencies. EBITDA margin for the full year 2005 more than doubled from 7% in fiscal 2004. Given our continued strong performance and the robust demand for our China products, we are confident in achieving our full year 2006 forecasts." Full Year 2005 results vs. forecasts - unit: million USD 2005 forecast 2005 actual % change Revenue 105.7 110.0 4 % EBITDA 16.7 21.2(1) 27 % Net Income 9.0 10.3 14 % Full Year 2006 forecasts - unit: million USD For 6 months For the year Revenue 74.7 166.0 EBITDA 11.5 25.6 Net Income 6.4 13.8 Full Year 2005 results (Japan GAAP(2)) - unit: million USD 2005 actual Revenue 110.0 EBITDA 18.8(1) Net Income (loss)(3) (2.8) (1) For FY2005 IFRS Reported EBITDA of US$21.2 mn and Japan GAAP Reported EBITDA of US$18.8 mn, the difference includes US$1.5 mn of one-time forex and sale of non-core assets gains, and US$0.9 mn of other GAAP reconciliatory items. (2) The main reason for the discrepancy between IFRS and Japan GAAP is that Japanese accounting standards take a different approach to accounting for goodwill from acquisitions. (3) Includes one-time charges of USD$4.4 million associated with fundraising activities. (Notes) A. We define EBITDA in relation to our IFRS financial statements as profit (loss) before interest, tax, depreciation and amortization. B. Forecasts for fiscal 2006 are management estimates only; figures have not been audited or reviewed. C. Performance estimates are determined based on information currently available. Due to unforeseen factors, actual performance may differ from estimates. About Xinhua Finance Limited Xinhua Finance Limited is China's unchallenged leader in financial information and media, and is listed on the Mothers board of the Tokyo Stock Exchange (symbol: 9399) (OTC ADRs: XHFNY). Bridging China's financial markets and the world, Xinhua Finance serves financial institutions, corporations and re-distributors through four focused and complementary service lines: Indices, Ratings, Financial News and Investor Relations. Founded in November 1999, the Company is headquartered in Shanghai with 18 offices and 21 news bureaus across Asia, Australia, North America and Europe. For more information, please visit http://www.xinhuafinance.com . For more information, please contact: Xinhua Finance Japan Mr Sun Jiong Tel: +81-3-3500-5328 Email: jsun@xinhuafinance.com China Ms Joy Tsang Tel: +86-21-6113-5999, +86-136-2179-1577, +852-3196-3983, +852-9486-4364 Email: joy.tsang@xinhuafinance.com Taylor Rafferty (IR Contact) Japan Mr. James Hawrylak Tel: +81-3-5733-2621 Email: james.hawrylak@taylor-rafferty.com United States Mr. Brian Rafferty Tel: +1-212-889-4350 Email: xinhuafinance@taylor-rafferty.com SOURCE Xinhua Finance Limited

BARCELONA, Spain, Feb. 14 /Xinhua-PRNewswire/ -- Aplix Corporation (TSE: 3727) announced today that they are collaborating on a platform to feature their JBlend(TM) Java(TM) technology running on Freescale's ARM11 processor with an optional NVIDIA graphics processing unit (GPU). These chipsets, when combined with the JBlend platform, result in a leading-edge demonstration, showcasing the depth and breadth of Java on mobile devices. At the heart of the demonstration is Freescale's i.MX31L multimedia applications processor. The i.MX31L features an ARM11(TM) processor core, designed to deliver high fidelity audio, as well as video playback, capture and conferencing for a stunning multimedia experience. The NVIDIA(R) GoForce(R) 5500 handheld graphics processing unit (GPU) compliments the i.MX31L multimedia capabilities maximizing the user experience for graphical Java applications, such as those using the Mobile 3D API (JSR-184). The ARM11 processor core is also at the heart of the Freescale's Mobile eXtreme Convergence MXC300-30 3G platform. "Our customers have come to know Aplix as the worldwide leader for Java on mobile phones," said Wesley Kuo, President and Chief Strategy Officer of Aplix Corporation. "Aplix continues this trend by constantly supporting new processor technologies, as highlighted in this exciting demonstration. We are very encouraged by our recent cooperation with Freescale and NVIDIA. Our partnerships with Freescale and NVIDIA enable us to integrate the leading features of JBlend with their offerings." "Consumers demand Java-driven applications on their mobile phones," said Brandon Tolany, operations manager of the multimedia applications division for Freescale Semiconductor. "Given our market leading family of i.MX applications processors, 3G platforms and revolutionary MXC architecture, coupled with the expertise and portfolio of Aplix and NVIDIA, this collaborative demonstration provides the solutions manufacturers need to deliver true multimedia-enabled handsets." "The combination of Freescale's i.MX processor and the NVIDIA GoForce 5500 handheld GPU provides the ultimate 3D performance platform for the Aplix JBlend Java solution," said Michael Rayfield, general manager of handheld GPUs at NVIDIA. "In addition, NVIDIA's close collaboration with Aplix ensures that content is fully optimized to take advantage of hardware acceleration for a compelling and immersive user experience." The 3GSM World Congress 2006 will be held from February 13 - 17 in Barcelona, Spain. The demonstration will be in Freescale's stand, located at B37. About Aplix Corporation Aplix Corporation is the global leader in deploying Java technology in mobile phones. Aplix was first established in 1986 and has been a Sun Java licensee since 1996. Aplix was publicly listed on the Tokyo Stock Exchange (Mothers) in 2003. On August 24, 2004 Aplix and the Taiwan based company iaSolution finalized the integration of the corporations. Headquarters: Tokyo Regional offices: San Francisco, Munich, Taipei, Shanghai, Beijing, and Korea (in progress) For more information, please visit: http://www.aplixcorp.com and http://www.iasolution.net . About the JBlend Platform The JBlend platform is the de facto solution for running Java applications and services in consumer electronics devices, including mobile phones. The platform has been licensed by over 50 companies as of December 2005. JBlend technology: -- Sets the pace by maintaining market leadership through innovation. -- Has proven results, enabling first-to-market deliveries for our customers. -- Over 150 million mobile phones and consumer electronics devices have been shipped with JBlend as of September 2005. About NVIDIA Corporation NVIDIA Corporation is the worldwide leader in programmable graphics processor technologies. The Company creates innovative, industry-changing products for computing, consumer electronics, and mobile devices. NVIDIA is headquartered in Santa Clara, CA and has offices throughout Asia, Europe, and the Americas. For more information, visit http://www.nvidia.com . -- JBlend and all related trademarks thereto are trademarks or registered trademarks of Aplix Corporation in Japan and other countries. -- Java and all other Java-based marks are trademarks or registered trademarks of Sun Microsystems, Inc. in the United States and other countries. -- All other product or service names are the property of their respective owners. For more information, please contact: Akiko Sharp Doi, Aplix Corporation Tel: +1-415-558-8800 Email: pr@aplixcorp.com Web: http://www.aplixcorp.com SOURCE Aplix Corporation

SCOTTS VALLEY, Calif., Feb. 14 /Xinhua-PRNewswire/ -- Convenos, provider of online meeting and collaboration services, today announced that Convenos Meeting Center, a Web conferencing and collaboration solution, is Skype(TM) certified. Convenos Meeting Center integrates meeting workspaces and Skype calls, making online collaboration truly cost effective and convenient. Convenos Meeting Center is available for 14-day trial or purchase from the Convenos Web site at: http://www.convenos.com/trynow.html . "Today's businesses are global in nature and require solutions that are convenient and cost effective to boost productivity and process improvements," says Thomas Torf, CEO of Convenos. "At Convenos, we are designing products to meet the demand for real-time collaboration solutions which clearly target process and productivity improvements, as well as cost reductions. By integrating Skype, Convenos Meeting Center enables groups of employees, customers, partners, and/or suppliers to collaborate and communicate more effectively at a fraction of the cost of other web conferencing tools." The Yankee Group has also found that software-as-a-service is gaining ground in the business applications market, as more than 60% of SMBs attribute "lower expense rates" and "increases in productivity" as driving factors for adopting software-as-a-service. Convenos Meeting Center offers subscription-based, flat-fee pricing and ease-of-use, combines the cost-saving advantages of Skype and a full set of industry-standard features, and is designed to ensure customers unprecedented value. With Convenos' flat-fee subscription hosts and attendees can meet as often and as long as they want, without incurring any additional meeting or telephone costs. Advantages of Convenos Meeting Center include: -- Unlimited online meetings hosted on Convenos servers -- Integrated Internet calling with no additional per-minute charges -- Industry-standard document, presentation, and application sharing -- Convenient meeting and attendee management from a secure, personalized web page -- Value-add tools such as chat, whiteboard, notes, and on-demand polling -- A range of meeting types, from instant meetings to presence-aware virtual workspaces -- Archival meeting details with persistent storage of shared meeting content -- Flat-fee pricing and absolutely no additional per-minute telephone charges Pricing and Availability Convenos Meeting Center is currently available for trial registrants and purchase from the Convenos website, http://www.convenos.com . Trial registrants have free and unlimited usage of a full-featured version of Convenos Meeting Center, including application sharing, polling, integrated Internet conferencing, for two weeks. After the trial period, Convenos Meeting Center is available for purchase for $30 per month or $300 per year, per host. Each Convenos Meeting Center subscription provides a named user the ability to host an unrestricted number of meetings. ABOUT SKYPE Skype is the world's fastest-growing service for Internet communication, allowing people everywhere to make unlimited voice calls for free. Skype is available in 27 languages and is used in almost every country around the world. Skype generates revenue through its premium service offerings such as making and receiving calls to and from landline and mobile phones, as well as voicemail and call forwarding services. Skype also has relationships with a growing network of hardware and software providers. Skype is an eBay company (Nasdaq: EBAY). To learn more visit http://skype.com . ABOUT CONVENOS MEETING CENTER Convenos Meeting Center is a powerful yet easy-to-use online collaboration environment which enhances productivity at any size organization. Convenos Meeting Center is simple and convenient to set-up and use, regardless of whether sessions are scheduled regularly or ad-hoc. The flat-fee pricing model is easy to understand and keeps an organization's collaboration costs predictable and under budget. Convenos Meeting Center is certified with Skype(TM) and integrated with Microsoft(R) Outlook to make it even easier and more intuitive for users to enjoy the advantages of online collaboration. ABOUT CONVENOS Convenos is dedicated to delivering online collaboration tools that are simple, convenient, and continue to advance the web-based collaboration and conferencing industries. Our products and services target innovations in the virtual workspace arena which leverage the convergence of web collaboration and on-demand applications and respond to business drivers in multiple industries and within businesses of any size. Convenos is committed to simplicity and convenience for the end user, easy implementation and management for the IT organization, excellence in the areas of security and compliance, and demonstrable value-add for all bottom-line stakeholders. For more information, please visit http://www.convenos.com . NOTE: Convenos(TM) and the Convenos logo are registered trademarks of Convenos Corporation. All product and company names mentioned herein may be the trademarks of their respective owners. For more information, please contact: Rebecca Cavagnari, Tel: +1-831-713-4609 Fax: +1-831-713-4605 Email: rcavagnari@convenos.com SOURCE Convenos Corporation

PRINCETON, N.J. and PHILADELPHIA, Feb. 14 /Xinhua-PRNewswire/ -- BioWa, Inc. and Aphton Corporation today announced that BioWa has granted a non-exclusive license to Apthon's wholly-owned subsidiary, Igeneon, to use BioWa's POTELLIGENT(TM) technology for the development of IGN312, a humanized monoclonal Lewis Y-specific antibody. Aphton, through Igeneon, develops IGN312 as a next-generation antibody based on IGN311, which is currently in a Phase I/II clinical trial in patients with Lewis Y-positive cancers. Aphton plans to use BioWa's POTELLIGENT(TM) technology for the development of a next-generation Lewis Y-specific antibody with enhanced antibody-dependent cellular cytotoxicity (ADCC). Lewis Y is a tumor-related antigen expressed in up to 90% of all epithelial cancers, which include breast, colon, gastric and pancreatic cancers. BioWa's POTELLIGENT(TM) technology has the potential to increase the ADCC activity of an antibody, resulting in greater capacity to destroy tumor cells. "We are very pleased to be working with an innovative cancer immunotherapy company like Igeneon, who has successfully progressed its antibody program to the clinical stage," said Nobuo Hanai, Ph.D., President and CEO of BioWa, Inc. "This licensing agreement enforces BioWa's strategy to bring about more effective and safe treatments for cancer." "We look forward to the rapid application of the POTELLIGENT(TM) technology, which has the potential to effectively increase the potency of IGN312 as an anti-cancer treatment," said Patrick Mooney, MD, Chairman and CEO of Aphton Corporation. "Entering into this partnership with BioWa is an important step in our efforts to continue to develop promising product candidates to fuel our clinical pipeline in the future." This agreement was mediated by FHR Consult ( http://www.fhrconsult.com ) on behalf of BioWa. About IGN311 and IGN312 IGN311 is a humanized monoclonal antibody against the Lewis Y carbohydrate antigen, a blood-group-related oligosaccharide. Lewis Y is over-expressed in up to 90% of all epithelial cancers and its expression on adult normal tissues is very restricted; hence IGN311 has the potential to target a broad range of carcinomas. IGN311 is designed to exert clinical effects by destruction of tumor cells by activation of effector functions and by selective growth inhibition via functional receptors. IGN312 is a next-generation antibody based on IGN311. About Aphton Corporation Aphton Corporation, headquartered in Philadelphia, Pennsylvania, is a clinical stage biopharmaceutical company focused on developing targeted immunotherapies for cancer. Aphton's products seek to empower the body's own immune system to fight disease. Through the acquisition of Igeneon AG in March 2005, Aphton acquired late-stage products, IGN101, a cancer vaccine designed to induce an immune response against EpCAM-positive tumor cells, as well as IGN311 and IGN312. Aphton has strategic alliances with Xoma for treating gastrointestinal and other gastrin-sensitive cancers using anti-gastrin monoclonal and other antibodies; Daiichi Pure Chemicals for the development, manufacturing and commercialization of gastrin-related diagnostic kits; and Celltrion for the development, manufacturing and commercialization of IGN311 in certain countries in Asia. Aphton's most advanced product, Insegia(TM), targets the hormone, gastrin 17, in an attempt to treat gastrointestinal cancers. Aphton is currently seeking partners to support the further development of Insegia. For more information about Aphton or its programs please visit Aphton's website at http://www.aphton.com . About POTELLIGENT(TM) Technology ADCC activity is an important function of the human immune system, whereby immune cells can kill target cells, e.g. cancer cells. As demonstrated by several anti-cancer therapeutic antibodies in the market today, ADCC activity plays a critical mechanism in the killing of tumor cells. Enhancement of this activity is one promising approach in the next generation of antibody technologies. POTELLIGENT(TM) technology involves the reduction of the amount of fucose in the carbohydrate structure of an antibody. Research shows that POTELLIGENT(TM) technology significantly enhances ADCC activity in vitro and in vivo. One potential benefit of POTELLIGENT(TM) technology derived therapeutic antibodies is greater tumor cell killing activity than with conventional antibodies. About BioWa, Inc. BioWa, Inc. is a wholly owned subsidiary of Kyowa Hakko Kogyo Co., Ltd., Japan's leading pharmaceutical and largest biotech company. BioWa is the exclusive worldwide licensor of POTELLIGENT(TM) technology, which creates high ADCC monoclonal antibodies. BioWa is currently developing ADCC enhanced monoclonal antibody-based therapeutics to fight cancer, asthma and other life-threatening and debilitating diseases and both BioWa and Kyowa have POTELLIGENT(TM) antibody products in various clinical stages. BioWa creates and develops enhanced ADCC antibodies for itself and others, offering a full range of antibody discovery and development capabilities. For more information about BioWa visit its web site at http://www.biowa.com . POTELLIGENT(TM) is the trademark of Kyowa Hakko Kogyo Co., Ltd. All rights are reserved. Safe Harbor This press release includes forward-looking statements within the meaning of the federal securities laws, including statements about Aphton's expectations regarding: (1) Aphton's plan to use BioWa's POTELLIGENT(TM) technology for the development of a next-generation Lewis Y-specific antibody with enhanced antibody-dependent cellular cytotoxicity; (2) the potential of BioWa's POTELLIGENT(TM) technology to increase the ADCC activity of an antibody, resulting in greater capacity to destroy tumor cells; (3) the potential benefits to Aphton resulting from the licensing agreement, including the rapid application of the POTELLIGENT(TM) technology in an attempt to effectively increase the potency of IGN312 as an anti-cancer treatment; (4) Aphton's belief that this new relationship with BioWa is an important first step in Aphton's efforts to continue to develop promising product candidates to fuel Aphton's clinical pipeline in the future; (5) the potential of IGN311 to target a broad range of carcinomas, destroy tumor cells, and exert clinical effects by destruction of tumor cells; and (6) Aphton's intent to seek partners to further support the development of Insegia. These forward-looking statements may be affected by risks and uncertainties that could cause the actual results to differ materially from those expressed in such forward-looking statements. Aphton undertakes no obligation to update forward-looking statements to reflect events or circumstances after the date hereof. This information is qualified in its entirety by cautionary statements and risk factor disclosure contained in Aphton's Securities and Exchange Commission filings, including Aphton's report on Form 10-K filed with the Commission on March 16, 2005. These risk factors include, but are not limited to: (1) the risks and uncertainties inherent in the drug development process and in Aphton's business; (2) the ability of Aphton and BioWa to successfully collaborate in the research and development of IGN312; (3) the possibility that BioWa's POTELLIGENT(TM) technology may not have the desired effect on antibodies; (4) the timing or results of ongoing and future clinical trials for IGN312; (5) the ability of Aphton to obtain regulatory approval for IGN312, fund the development, manufacture and commercialization of IGN312, and gain commercial acceptance of IGN312; (6) the ability of any approved third parties to manufacture and supply IGN312 in commercial quantities; (7) the ability of Aphton to fund the development, manufacturing and commercialization of IGN312; (8) Aphton's ability to find a partner who will support the further development of Insegia; (9) intellectual property risks; (10) the impact of competitive products and pricing; and (10) changing economic conditions. For more information, please contact: Nobuo Hanai, Ph.D., President and CEO BioWa, Inc. Tel: +1-609-580-7500 x7501 Martina Molsbergen, Vice President, Business Development BioWa, Inc. Tel: +1-609-580-7500 x7506 Patrick Mooney, M.D., President and CEO, Aphton Corporation Tel: +1-215-218-4377 Gerda Redl, Ph.D., Vice President, Business Management Aphton Corporation Tel: +43-1-90250-122 SOURCE BioWa, Inc.

SALT LAKE CITY, Feb. 14 /Xinhua-PRNewswire/ -- Zygote Media Group, Inc., the leading provider of world-class 3D biomedical models, images and animations, today announced the public availability of the Zygote Human Heart 3, the most sophisticated 3D heart model ever. The Zygote heart is the only known animated 3D heart model available for licensing in the world. (Photo: http://www.newscom.com/cgi-bin/prnh/20060213/LAM154-a http://www.newscom.com/cgi-bin/prnh/20060213/LAM154-b ) New detail from MRI and CT data make the imagery as close to the real thing as anything existing on the market today. Zygote Human Heart 3 makes it easy for graphics designers, scientists and animators to visualize the human heart, from exteriors and cut views of the interior to an accurate animation of the cardiac cycle. The model and images are available for immediate licensing at http://www.3DScience.com . "Zygote Human Heart 3 is a breakthrough product. Not only is it the greatest heart 3D model ever, it is one of those once-in-a-generation products that redefines its category," said Bryan Brandenburg, CEO of Zygote Media Group. "This is the first and only animated 3D heart model ever to be derived from high resolution MRI and CT data and available for licensing. If a picture is worth a thousand words, then this animation is worth millions." The Zygote Human Heart 3 offers customers: -- More MRI/CT human heart detail with a reduced polygon count -- Full human heart cardiac cycle that includes cutaway interior views -- Two high resolution photorealistic exterior texture maps for both a lean and fatty heart derived from human heart digital photos -- Support for most major 3D applications including Maya, 3D Max, Lightwave, Cinema4D, Softimage, Shade and Generic OBJ The Highest Detailed 3D Heart Model Ever Almost any view of the human heart can be visualized, including human heart diagrams, heart anatomy pictures, and accurate human heart animations. The virtual heart model features cuts so not only is the interior viewable at great detail, but is also revealed while animating the cardiac cycle. Pricing and Availability The Zygote Human Heart 3 retail price starts at $1,200. From now until March 15, there is an introductory discount of 30%. Students, educators and educational institutes receive an additional 30% off as part of 3DScience.com's educational discount program. Texture maps, cuts and animation files can be purchased separately. Other heart models are also available including the standard heart for $99 and a solid heart model for design and engineering at $2,500. About Zygote Media Group With more than 11 years of development, Zygote's library of licensable content boasts the most comprehensive and accurate collections of anatomical 3D models available in the world. Zygote is located near Salt Lake City, Utah and can be found at http://www.zygote.com , or by calling (801) 765-4141. About 3DScience.com 3DScience.com is an online marketplace and community dedicated to scientific visualization and supporting educators around the world. 3DScience.com is the home of the Zygote Male and Female Anatomy 3D Model collections. http://www.3DScience.com also provides a wide range of 3D Models, stock medical illustrations as well as the highest quality library of free medical clip art available on the World Wide Web. 3DScience.com is powered by GoECart.com Shopping Cart Software. Note: Content for the media can be found at: Human Heart Pictures available as Free Clip and Licensing at higher resolution http://www.3dscience.com/human_heart_anatomy_pictures.asp Human Heart Anatomy Diagrams http://www.3dscience.com/human_heart_anatomy_diagram.asp Human Heart Anatomy Animation http://3dscience.com/heart_model_animation.asp Human Heart Model http://3dscience.com/human_anatomy_3d_heart_model2.asp Valentine's Day Heart, Valentine's Heart http://3dscience.com/valentines_day_heart.asp For more information, please contact: Tim Rush, Snapp Norris Group, Zygote Media Group, Inc. Tel: +1-801-208-1100 Email: tim.rush@sng.com, SOURCE Zygote Media Group, Inc.

International Trade Commission
WASHINGTON, Feb. 14 /Xinhua-PRNewswire/ -- Sughrue Mion PLLC, a leading global intellectual property law firm, announced today that they will sponsor a two-day mock trial seminar at Kangnam GS Tower in Seoul in conjunction with the Korean Patent Attorneys Association (KPAA). The program will highlight the difficult and unique challenges that Korean companies face when confronted with patent litigation in U.S. federal courts and before the International Trade Commission (ITC). "As a firm that has been active in the U.S. and Asia for decades, we've seen a trend as Asian companies become more aggressive in enforcing their own patents," Bill Mandir, a Sughrue Mion partner who led the design of this program, said. "These battles often get played out with U.S. patents in U.S. district courts and the ITC because of the enormous market the U.S. offers. After the success of our Japanese mock trial events, we recognized the importance of reaching an even greater breadth of our Asian clients." The mock trial will be presented to an American-style jury and presided over by the Honorable James F. Stiven, a retired U.S. Magistrate for the Southern District of California with more than 35 years of trial experience. The 250 Korean in-house counsel and corporate managers expected to attend the event will be able to see exactly how a jury deliberates and the issues that are of paramount concern to them. The trial itself will center on a mock case where a U.S. plaintiff has alleged that a Korean defendant has infringed on patented technology for golf club grips. The courtroom will be modeled after a U.S. courtroom, and all aspects of the litigation and deliberation will be filmed so that participants can see what happens during the trial and in the jury room. "The ITC continues to be an increasingly popular venue for patent litigation, so it was important to add this element to the mock trials in Korea," John Rabena, a Sughrue Mion partner, said. "Through this mock trial we will help explain the differences between U.S. and Korean courts -- and the differences between district courts and the ITC -- and help our clients develop a winning strategy if they are called into a case. And, as a result of this experience, we expect companies will see how to better build their patent portfolios to avoid litigation altogether." Sughrue partners Steve Gruskin, Carl Pellegrini, and John Scherling, all of whom have extensive litigation experience, have also been involved in planning the mock trial. To register for the event, please download the registration form at http://www.kpaa.or.kr , call the Korean Patent Attorneys Association at 822-8486-8486, or email gn@kpaa.or.kr. About Sughrue Mion, PLLC Sughrue Mion, PLLC, is one of the largest law firms practicing exclusively in the field of intellectual property law. Based in Washington, D.C. with offices in Silicon Valley, San Diego, and Tokyo, Sughrue specializes in litigating intellectual property matters in federal district court and before the International Trade Commission. Sughrue has obtained more patents than any other firm in the country. For more information please visit http://www.sughrue.com . For more information, please contact: Melissa Maslar, Sughrue Mion PLLC Tel: +1-202-973-1336 Mobile: +1-202-276-0070 Email: mmaslar@levick.com, SOURCE Sughrue Mion PLLC

ST. PAUL, Minn., Feb. 14 /Xinhua-PRNewswire/ -- Merrill Corporation today announced that it has filed a registration statement with the U.S. Securities and Exchange Commission in connection with a proposed initial public offering of its common stock. The proposed offering will include shares sold by Merrill Corporation and by certain of Merrill's stockholders including DLJ Merchant Banking Partners II, L.P. Deutsche Bank Securities Inc. and Credit Suisse Securities (USA) LLC will be acting as joint book-running managers and Piper Jaffray & Co. will be a co-manager. The number of shares to be offered and the price range for the offering have not yet been determined. The offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus relating to this offering may be obtained from Deutsche Bank Securities Inc., Prospectus Department, Floor 25, 1251 Avenue of the Americas, New York, NY 10020, (212) 250-2500 or Credit Suisse Securities (USA) LLC, Prospectus Department, Eleven Madison Avenue, Level 1B, New York, NY 10010, (212) 325-2580. A registration statement relating to these securities has been filed with the Securities and Exchange Commission, but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Merrill Corporation Merrill Corporation, headquartered in St. Paul, Minnesota, is a leading provider of outsourcing solutions for various complex business communication and information management needs. Merrill's services include document and data management, litigation support, branded communication programs, fulfillment, imaging and printing. Forward-Looking Statements Certain statements in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to various risks, uncertainties and assumptions that could cause actual results to differ materially from those contained in the forward-looking statements. A discussion of the factors that could cause results to differ materially is included in Merrill Corporation's Form S-1 filed with the Securities and Exchange Commission. For more information, please contact: Craig Levinsohn, Merrill Corporation Tel: +1-651-632-4505 Email: Craig.levinsohn@merrillcorp.com SOURCE Merrill Corporation

NEW YORK, Feb. 14 /Xinhua-PRNewswire/ -- McGraw-Hill Aerospace & Defense has reached agreement with the new ownership of the Singapore Air Show, to be its Official Media Partner commencing with the February 26-2 March, 2008 event at Singapore's Changi International Airport. McGraw-Hill A&D and its Aviation Week information and media products will support the Singapore show, now known as Changi International Airshow (CAS) with print, electronic and event access to its audience of 1.2-million aviation, aerospace and defense professionals in 180 countries. The agreement includes cooperative advertising, event advisory, exclusive distribution points, and marketing programs. Aviation Week & Space Technology and Aviation Week ShowNews, a daily magazine produced on-site in Singapore, will be the lead publications for CIAS. In addition, the group's Business & Commercial Aviation, Overhaul & Maintenance, Defense Technology International, AviationNow.com, and Aviation Week Conferences & Exhibitions will be involved in the global communications program for the air show. "Our relationships with the Singapore business community, the show organizers and the Asian aerospace industry spans several decades, and we welcome this opportunity to step up to a new level of involvement and support as the region paces development in aerospace and defense," said McGraw-Hill Aerospace & Defense Executive Vice President/Publisher Kenneth E. Gazzola "Moreover, our media and information services lend a powerful foundation as the event transitions to new ownership and venue." The new ownership of CAS is investing millions to elevate the importance of the event. This includes moving the event to a new runway with access to the static line, new exhibit chalet and exhibition facilities, installing a modern communications and IT infrastructure, and reaching an agreement with a new media partner that can bring a global, multimedia presence to the show. "Aviation Week provides the Changi International Airshow with global leadership in all key world regions and industry sectors, including commercial air transport, military, space, business aviation and MRO," said Jimmy Lau, Managing Director, of CAS. "In addition, our growing event and markets provide Aviation Week a new level of visibility throughout Asia." About McGraw-Hill Aerospace & Defense McGraw-Hill Aerospace & Defense, a division of The McGraw-Hill Companies, is the largest multimedia information and services provider to the global aviation and aerospace industry, and includes publications such as Aviation Week & Space Technology, Defense Technology International, Aviation Daily, Overhaul & Maintenance, Aerospace Daily & Defense Report, ShowNews, Business & Commercial Aviation, The Weekly of Business Aviation, and the World Aerospace Database and its print companion, World Aviation Directory. The group's web portal, http://www.aviationnow.com , offers the industry's most reliable news, information, intelligence and features, and its Aviation Week Intelligence Network (AWIN) at http://www.aviationweek.com/awin is the industry's most integrated business tool for managers, business developers, buyers and technical professionals across the entire aviation and aerospace field. McGraw-Hill A&D also produces 12 executive events in the MRO and Programs and Defense sectors. About The McGraw-Hill Companies Founded in 1888, The McGraw-Hill Companies is a leading global information services provider meeting worldwide needs in the financial services, education and business information markets through leading brands such as Standard & Poor's, McGraw-Hill Education, BusinessWeek and J.D. Power and Associates. The Corporation has more than 290 offices in 38 countries. Sales in 2005 were $6.0 billion. Additional information is available at http://www.mcgraw-hill.com . About Changi International Airshow Changi International Airshow (CAS) will be held in Singapore on a biennial basis, beginning 26 February 2008. The event is organized by Changi International Airshow & Events Pte Ltd., a joint venture between the Civil Aviation Authority of Singapore (CAAS) and the Defence Science & Technology Agency (DSTA), a subsidiary of Singapore's Ministry of Defence. Managing Changi International Airshow & Events Pte Ltd are Chairman, Lim Chin Beng, an aviation veteran, and Jimmy Lau, former Managing Director of Asian Aerospace Pte Ltd. For more information, please contact: Rob Kulat Kulat Communications Tel: 732-219-5816 Email: kucomm@hotmail.com SOURCE McGraw-Hill Aerospace & Defense

HONG KONG, Feb. 14 /Xinhua-PRNewswire/ -- Telecom Communications, Inc. (OTC Bulletin Board: TCOM) the Total Solutions Provider, announced operating statistics for the quarter ended December 31, 2005. Revenues increased $2,752,761 or 174.7% due primarily to: Revenues recorded at $4,328,099 for the three months period ended December 31, 2005 compared to $1,575,338 for the same period ended December 31, 2004. The increase of $2,752,761 due primarily to the initial receipt of rights to first use the software of $2,400,000. Revenues for the period ended December 31, 2005 were generated from the fixed monthly income by providing clients our products namely Total Solutions, SEO4Mobile and IBS V4.1. Net income was up 35.9% to $493,368 for the three month period ended December 31, 2005 compared to $362,965 for same period ended December 31 of 2004. "Our first quarter 2006 results include strong performance in total solutions product lines and IBS v4.1 SMEs sales," said Tim Chen, president and CEO of TCOM. "We are encouraged by the fact that IBS v4.1 sales continue to build momentum and generate increased interest from SMEs Internet businesses business. Cash used during the quarter includes our continued investment in our SME software system developments called IBS v5.0 as BtoBtoC e-commerce value chain, and entertainment content service offerings." TCOM will report its 1st quarter 2006 financial results within this week. About Telecom Communications, Inc. Telecom Communications, Inc. is a Total Solutions Provider that offers Integrated Communications Network Solutions and Internet Content Services in universal voice, video, data web and mobile communications for interactive media applications, technology and content leaders in interactive multimedia communications. It develops, markets and sells a universal media software solution for enterprise-wide deployment of integrated voice, video, data web and mobile communications and media applications. Telecom Communications, Inc. does business in Asia via its wholly owned subsidiaries, Alpha Century Holdings Ltd and 3G Dynasty Inc. (http://www.icstarmms.com ; http://www.skyestar.com ). icstarmms.com currently provides entertainment contents to 64 China Internet companies including: http://www.Baidu.com , Shanghai Linktone, 3721.com -- a Yahoo company, Kongzhong Corp., http://www.QQ.com and http://www.eLong.com under the cooperation partnership agreements. About IBS v4.1 Enterprise Suite The product line focuses on the one million SMEs in China, with version 4.1 enterprise suite being satiable to all companies with less than 500 employees, inner information resource management and affiliate networks, vendor/customer, information process and communications over the Internet and wireless communications. This product has strong customer relations and interactive management, straight to the end consumer via MoDirect. Most SMEs have only small budgets for promotion, marketing and customer management. They can use IBS v4.1 at the lowest cost to publish ads on the web and SEO4Mobile mobile phone users. The product allows quick and easy interaction between company and customer straight to the end consumers. Safe Harbor The statements made in this release constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect," or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, changing economic conditions, interest rates trends, continued acceptance of the Company's products in the marketplace, competitive factors and other risks detailed in the Company's periodic report Filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. For more information, please contact: Ms. Sandy Tang Telecom Communications, Inc. Tel: +852-2782-0983 Email: pr@tcom8266.com SOURCE Telecom Communications, Inc.

DUSSELDORF, Germany, Feb. 14 /PRNewswire/ -- After the successful completion of clinical studies, the German biotech company Orthogen AG (Dusseldorf) intends to build up a Europe-wide distribution of Orthokine(R). Orthokine(R) is a medical device for the production of autologous conditioned serum; containing anti-inflammatory cytokine antagonists and growth factors. Two universities performed randomized double-blind studies demonstrating its high efficacy and safety in the therapy of osteoarthritis of the knee and low back pain. "Due to its beneficial side effect profile, Orthokine(R) therapy represents an efficient alternative to steroids, hyaluronic acids and analgesics like cox-II inhibitors," said Prof. Dr. Peter Wehling, CEO of Orthogen, today. After the build up of the Germany-wide sales in the last year, the molecular orthopedics specialist company intends to extend its activities to the EU market. FDA application for the sales in the US market is filed. Orthogen AG works currently on a novel stem cell technology for the regeneration of cartilage from non-embryonic stem cells. First clinical results on humans demonstrate feasibility of the method. It is intended to replace time-consuming autologous chondrocyte implantation (ACI) by this new procedure. A new immune-modulatory therapeutic approach for the treatment of rheumatoid arthritis with so-called exosomes is also under development. Exosomes are highly efficient anti-inflammatory nano-particles. Clinical studies demonstrated feasibility and safety of the method. Further clinical studies are intended to show long-term-efficacy. This method could become a highly efficient and safe alternative to cytokine antagonists produced with recombinant techniques (e.g. Anti-TNF). Orthogen AG is a biopharmaceutical group of companies which has worked for twelve years in the field of molecular orthopedics. For more information, please contact: Antje Kassel Public Relations Orthogen AG Tel: +49-(0)211-387-0076 Mobile: +49-173-240-2901 Fax: +49-(0)211-387-0010 Email: akassel@orthogen.com Website: http://www.orthogen.com SOURCE Orthogen AG

BARCELONA, Spain, Feb. 13 /Xinhua-PRNewswire/ -- 3GSM World Congress 2006 -- ANADIGICS, Inc. (Nasdaq: ANAD), a leading supplier of wireless and broadband solutions, today introduced its third generation High-Efficiency-at-Low-Power (HELP3(TM)) wideband CDMA (WCDMA) power amplifiers (PAs). The Company's HELP3(TM) WCDMA PAs offer the industry's lowest power consumption and provide full compliance with High Downlink Packet Access (HSDPA) requirements, enabling ultra-fast multimedia access, while extending battery life. The complete family of HELP3(TM) WCDMA PAs has been optimized for power and space sensitive 3G devices, including handsets, smart phones, data cards, and embedded notebook applications. "ANADIGICS is raising the performance bar for 3G power amplifiers with our latest generation of HELP(TM) products," said Dr. Ali Khatibzadeh, Senior Vice President and General Manager of Wireless Products at ANADIGICS. "Our HELP3(TM) HSDPA-compliant power amplifiers offer the industry's best current consumption, allowing mobile users to experience the full potential of 3G services." ANADIGICS' HELP3(TM) PAs use the Company's exclusive InGaP-Plus(TM) technology, which integrates bipolar and field-effect transistor (FET) devices on the same InGaP GaAs die. Through selectable bias modes, the HELP3(TM) PAs achieve optimal efficiency across the low-range and mid-range output power levels. The PAs reduce average current consumption by 75%, compared with a conventional power amplifier. This represents an additional 50% average current consumption savings compared with the first generation HELP(TM) WCDMA PAs. HELP3(TM) PAs provide exceptionally low quiescent currents of 7 mA without an external DC-DC converter. They also incorporate a built-in reference voltage generator eliminating the need for external regulators. Part Number Frequency Band Efficiency Quiescent Current AWT6273 824 MHz to 849 MHz 45% @ +29 dBm 7 mA (US Cellular) 20% @ +16 dBm AWT6278 1850 MHz to 1910 MHz 43% @ +29.5 dBm 7 mA (US PCS) 21% @ +16 dBm AWT6279 1920 MHz to 1980 MHz 43% @ +28.5 dBm 7 mA (IMT) 21% @ +16 dBm The new power amplifiers are offered in compact 4 mm by 4 mm by 1 mm modules. The products are manufactured using a materials set consistent with the European Union's Restriction of Hazardous Substances (RoHS). The AWT6273, AWT6278, AWT6279 are priced at $2.58 in quantities of 10,000 units. Samples are available now. For additional information, contact ANADIGICS by phone (908) 668-5000 or FAX (908) 668-5132 or visit the Company's Web site at http://www.anadigics.com . ANADIGICS, Inc. (Nasdaq: ANAD) designs and manufactures radio frequency integrated circuit (RFIC) solutions for growing broadband and wireless communications markets. The Company's innovative high frequency RFICs enable manufacturers of communications equipment to enhance overall system performance, and reduce manufacturing cost and time to market. By utilizing state-of-the-art manufacturing processes for its RFICs, ANADIGICS achieves the high-volume and cost-effective products required by leading companies in its targeted high-growth communications markets. ANADIGICS was the first GaAs IC manufacturer to receive ISO 9001 certification and is certified to the ISO 9001:2000 and ISO 14001:2004 international standards. Except for historical information contained herein, this press release contains projections and other forward-looking statements (as that term is defined in the Securities Exchange Act of 1934, as amended). These projections and forward-looking statements reflect the Company's current views with respect to future events and financial performance and can generally be identified as such because the context of the statement will include words such as "believe", "anticipate", "expect", or words of similar import. Similarly, statements that describe our future plans, objectives, estimates or goals are forward-looking statements. No assurances can be given, however, that these events will occur or that these projections will be achieved and actual results and developments could differ materially from those projected as a result of certain factors. Important factors that could cause actual results and developments to be materially different from those expressed or implied by such projections and forward-looking statements include those factors detailed from time to time in our reports filed with the Securities and Exchange Commission, including the Company's annual report on Form 10-K for the year ended December 31, 2004, and those discussed elsewhere herein. For more information, please contact: Press Chuck Manners Godfrey Tel: +1-717-393-3831 Fax: +1-717-393-1403 Email: chuck@godfrey.com Corporate Contact Brian Ribeiro ANADIGICS, Inc. Tel: +1-908-668-5000 Fax: +1-908-412-5978 Email: bribeiro@anadigics.com Investor Relations Thomas Shields ANADIGICS, Inc. Tel: +1-908-412-5995 Email: tshields@anadigics.com SOURCE ANADIGICS, Inc.

BARCELONA, Spain, Feb. 13 /Xinhua-PRNewswire/ -- 3GSM World Congress -- From today BullGuard Mobile Anti-virus will be available as a multi-platform retail pack, for mobile devices using Windows Mobile and Symbian operating systems. The pack includes full automatic anti-virus protection and access to BullGuard Support 24-hours a day. BullGuard Mobile Anti-virus retail pack: -- 1 Year BullGuard Mobile Anti-virus subscription -- Software for Windows Mobile and Symbian Series 60/80/UIQ devices -- Available in 16 languages -- Includes BullGuard Support BullGuard's COO Heini Zachariassen commented on the product launch: "Over the past year we have learned from our partners that there is great demand for a single retail product covering all the major mobile platforms. With this new retail product covering 5 different operating systems and allowing users to change device during the subscription period, we have brought the most complete solution to the marketplace." BullGuard Mobile Anti-virus BullGuard Mobile Anti-virus includes constant traffic monitoring and on-demand scanning in addition to automatic over-the-air updates. Launched in March 2005, and available as a retail product for Windows Mobile platforms since June 2005, BullGuard Mobile Anti-virus is a standard installation on devices sold by leading European operators including Sonofon, Telefonica, ONE and devices configured by Dangaard Telecom, Europe's largest mobile phone distributor. Features -- On-writing Anti-virus Scanner Scans all files downloaded from the internet or received via e-mail, SMS, MMS, Bluetooth, IR. -- On-demand Anti-virus Scanner Customisable search of selected files/folders. -- Over-the-air Virus Definition Updates Updates are received and installed automatically. -- On-device alerting function BullGuard Mobile Anti-virus alerts the user when malware is identified and automatically responds to the threat. -- Scan logs All recent scans are logged with details of any malware identified. -- Available in 16 languages: Arabic, Chinese (Mandarin), Danish, Dutch, English, Flemish, French, German, Greek, Hungarian, Italian, Norwegian, Portuguese, Russian, Spanish and Swedish. -- BullGuard Support It is central to the BullGuard concept of Security that our customers receive all the assistance needed to fully appreciate and utilise the BullGuard products. BullGuard Support is a free service, available 24 hours a day, 365 days a year, offering advice and assistance whenever it is needed. About BullGuard BullGuard specialises in PC & mobile security solutions for home-users and small-businesses, emphasising technical excellence, ease-of-use and customer-care. BullGuard is committed to providing simple, cost-effective, integrated security solutions that provide users with first-class protection from computer viruses and intruders. BullGuard 6.0 is available as Retail, OEM and ESD. BullGuard is headquartered in Copenhagen, Denmark and has offices in Romania and the United Kingdom. For more information, please contact: Alexander Staun-Rechnitzer, Information and PR Manager, BullGuard Mobile: +45-2682-1982 Email: alex@bullguard.com Web: http://www.bullguard.com SOURCE BullGuard Ltd.

BEIJING, Feb. 13 /Xinhua-PRNewswire/ -- Xinhua China (OTC Bulletin Board: XHUA) the majority shareholder of the leading book distributor in China, reported today that it expects the number of titles entered into its Chapter One China(TM) system to exceed 10,000 before the end of February. The company also expects the number of titles available through the Chapter One system to continue increasing beyond that level in the near future. It said the rate of entry is accelerating and a wider variety of titles is being included. The only system of its kind in China, Chapter One China allows book retailers and others in the Chinese market to preview, through an on-line portal, titles they are considering stocking in their stores. Among the titles being entered are textbooks, engineering and technical volumes, literature, biographies, historical texts and other non-fiction. Titles in Chinese and other languages, most notably English, are increasingly available for preview through the system. Book buyers have the ability to search the database by title, author, publisher and ISBN code and review the first chapter of any title before making a buying decision, according to Xinhua China. Xianping Wang, president and CEO said, "The ability to preview volumes on-line before making purchases is particularly important in China because of the distances involved in some areas. Chapter One China will allow bookstores in even the farthest provinces to make buying decisions and stock titles that meet the needs of their specific customers with the same speed and efficiency available in major population centers. "Our ultimate goal is to make available for preview on the Chapter One China system every title available in the Chinese market. We have the capacity to do so and we are well on our way toward that goal," Wang added. Wang noted that Xinhua China expects the development of the Chapter One system to be a significant factor in the growth of its operating subsidiary, Xinhua Publications Circulation & Distribution Co., Ltd. "We expect to benefit from Chapter One in a variety of ways. We expect to reach agreements with many of the over 12,800 government-owned Xinhua bookstores, the thousands of independent bookstores and on-line booksellers under which we will provide access to the Chapter One system in return for certain order volume placed through Xinuha C & D. We will also provide them with the option to subscribe to the system for a modest annual fee." "The Chapter One system should also prove valuable to on-line booksellers. It will allow their customers to review excerpts before making a purchase -- the equivalent of browsing through a bookstore. The growth of on-line purchasing of books and other publications in China provides an additional opportunity to grow our business. On-line sales require fulfillment services. We are uniquely positioned to provide those services by shipping titles directly to consumers on a fee-for-service basis. The number of Internet users in China is projected to reach 600 million by the year 2010. Internet commerce potentially represents a major source of revenue and earnings for Xinhua China," Wang concluded. About Xinhua China Xinhua China Ltd. is a U.S. publicly traded holding company that, through one of its subsidiaries, Xinhua Publications Circulation & Distribution Co., Ltd., holds a national license for distribution of books and other publications in China. Xinhua China is involved in forming strategy, operating and financing for Xinhua C & D. Xinhua China also interfaces with the worldwide financial communities to inform them of the combined companies' goals and developments. For more information, please call Mr. Alex Helmel at 1-800-884-3864 ext. 17 or visit its website at http://www.xinhuachina.com.cn . Safe Harbor Statement This news release may include forward-looking statements within the meaning of section 27a of the UNITED STATES SECURITIES ACT of 1933, as amended, and section 21e of the UNITED STATES SECURITIES and EXCHANGE ACT of 1934, as amended, with respect to achieving corporate objectives, developing additional project interests, Xinhua China's analysis of opportunities in the acquisition and development of various project interests and certain other matters. These statements are made under the "safe harbor" provisions of the United States private securities litigation reform act of 1995 and involve risks and uncertainties, which could cause actual results to differ materially from those in the forward-looking statements contained herein. For further information, please contact: At Xinhua China Ltd.: Alex Helmel Investor Relations Tel: +1-604-681-3864 or +1-800-884-3864 Email: info@xinhuachina.com.cn At The Investor Relations Company: Woody Wallace or Michael Arneth Tel: +1-847-296-4200 Email: wwallace@tirc.com or marneth@tirc.com SOURCE Xinhua China Ltd.

Hospital and Equipment Divisions Report Profitable Operations;
Closedown of Distribution Division in Process
BETHESDA, Md., Feb. 13 /Xinhua-PRNewswire/ -- Chindex International, Inc. (Nasdaq: CHDX), an independent American provider of Western healthcare products and medical services in the People's Republic of China, today announced results for the quarter ended December 31, 2005. The Company will report a 22% increase in consolidated revenue over the same quarter of the prior fiscal year and an after-tax loss. The Medical Capital Equipment and Healthcare Services divisions both reported profitable operations while the Healthcare Products Distribution division accounted for the loss in the quarter as closedown of operations in this division were initiated. Revenue for the quarter ended December 31, 2005 was $27.2 million with a loss from operations of $516,000 and a net loss of $463,000 or a loss per share of $0.07. This compares to revenue of $22.3 million with a loss from operations of $3.3 million and a net loss of $3.7 million, or a loss per share of $0.69, for the quarter ended December 31, 2004. Revenue for the nine months ended December 31, 2005 was $77.8 million with a loss from operations of $2.8 million and a net loss of $2.5 million, or a loss per share of $0.39. This compares to revenue of $76.6 million with a loss from operations of $2.8 million and a net loss of $3.6 million, or a loss per share of $0.68, for the nine months ended December 31, 2004. Roberta Lipson, President and CEO of Chindex commented from the Company's offices in Beijing: "During the recent quarter we reported strong revenue growth in the Healthcare Services segment of 91%, as compared to the prior year period. We reported modest revenue growth in the Medical Capital Equipment segment of 7% in spite of continuing market challenges. The results for the period were a significant improvement over the prior year with both the equipment and hospital divisions reporting profitable operations. In addition, we had a significant decrease in expenses at the parent company level. Although we reported a consolidated loss, it was attributable to the results of the Healthcare Products Distribution division which we began closing down following our announcement on November 23, 2005. "In the Healthcare Services segment we are very pleased to see that the United Family Hospital network has continued to increase its profitability on a consolidated basis this quarter based on revenue growth system-wide. Growth continues in both the Beijing and Shanghai markets and we expect continued profitability from this division. We closed on a long-term financing package with the International Finance Corporation of the World Bank for approximately $8 million during the quarter which is now providing us with capital funding for expansion projects throughout the United Family Hospital network and which has allowed us to restructure our balance sheet debt along more traditional hospital ratios. Our formal accreditation from the Joint Commission International of the United Family Hospital network operations in Beijing sets us distinctly apart from any other healthcare network in Asia. It is a strong, global affirmation from the premier accreditation agency in the health services industry of our quality standard at United Family Hospitals. This is the hallmark of our brand value. We are the first hospital network in Asia to receive this accreditation. "In the Medical Capital Equipment segment our results included delivery of goods under the current phase of our German KfW financing package which helped to offset the continuation of several factors which are impacting our results so far this year. These include lacklustre sales in certain product categories due to maturing product life cycle issues, increased competition in certain mid-tier product markets and delays due to product registrations in other product categories. We continue to focus on cost containment and have new premium and mid-tier market product releases scheduled during the fourth quarter. In addition, the product registration process has recently been completed for another line of products that has allowed sales to proceed. We have experienced such down periods in the capital equipment business before in China. We believe there is basically no change to the underlying demand for the products and services we provide to the Chinese hospital markets. "On November 23, 2005, we announced that we would close down operations of the retail pharmacy distribution business, which comprises most of the operations of the Healthcare Products Distribution segment. The logistics operations of the segment will migrate to the parent company level and continue to provide services to other business units of the Company. During the recent quarter, the business operations of the segment generally continued to be routine as the closedown process began. The closedown process of the retail pharmacy business is continuing at the time of this release. Our objective is to minimize the overall costs to the Company through the careful migration of personnel where possible and realization of assets. Although we originally expected the closedown to be substantially completed by December 31, 2005, managing the process in order to reduce associated costs to us has extended the implementation timeline beyond our original estimate by a few months." About Chindex Chindex is an American healthcare company supplying both medical equipment and healthcare services to the Chinese marketplace, including Hong Kong. It sells medical equipment produced by a number of major multinational companies including Siemens AG as its exclusive distribution partner for the sales and servicing of color doppler ultrasound systems. It also arranges financing packages for the supply of medical equipment to hospitals in China utilizing the export loan and loan guarantee programs of both the U.S. Export-Import Bank and the German KfW Development Bank. It provides healthcare services through the operations of its network of private primary care hospitals and affiliated ambulatory clinics in China. With twenty-four years of experience, approximately 1,000 employees, and operations in the United States, China and Hong Kong, the Company's strategy is to expand its cross-cultural reach by providing leading edge healthcare technologies, quality products and services to Greater China's professional communities. Further company information may be found at the Company's websites, http://www.chindex.com and http://www.unitedfamilyhospitals.com . Some of the information in this press release may contain statements regarding future expectations, plans, prospects for performance of the Company that constitute forward-looking statements for purposes of the safe harbor provisions of The Private Securities Litigation Reform Act of 1995. The Company cannot guarantee future results, levels of activity, performance or achievements. The numbers discussed in this press release also involve risks and uncertainties. The following factors, among others, could cause actual results to differ materially from those described by such statements: our ability to manage our growth and maintain adequate controls, our ability to obtain additional financing, the loss of services of key personnel, general market conditions including inflation or foreign currency fluctuations, our dependence on relationships with suppliers, the timing of our revenues and fluctuations in financial performance, the availability to our customers of third-party financings, product liability claims and product recalls, competition, hiring and retaining qualified sales and service personnel, management of inventory, relations with foreign trade corporations, dependence on sub-distributors and dealers, completion and opening of healthcare facilities, attracting and retaining qualified physicians and other hospital personnel, regulatory compliance, the cost of malpractice, our dependence on our information systems, the economic policies of the Chinese government, the newness and undeveloped nature of the Chinese legal system, the regulation of the conversion of Chinese currency, future epidemics in China such as SARS or Avian Flu, the control over our operation by insiders, continuity of relationships and variability of financial margins with existing suppliers, our liquidity and availability of capital resources to meet cash requirements, including capital expenditures, bid and performance bonds, limitations on the inter-entity transfers and other limitations imposed by existing credit facilities, uncertainty about the costs related to the closedown of the Healthcare Products Distribution segment, and those other factors contained in the section titled "Risk Factors" as set forth in the Company's Registration Statement (File No. 333-114996) declared effective by the Securities and Exchange Commission on December 5, 2005, as well as other documents that may be filed by the Company from time to time with the Securities and Exchange Commission. The forward-looking statements and numbers contained herein represent the judgment of the Company, as of the date of this press release, and the Company disclaims any intent or obligation to update such forward-looking statements to reflect any change in the Company's expectations with regard thereto or any change in events, conditions, circumstances on which such statements are based. CHINDEX INTERNATIONAL, INC. CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS (thousands except share and per share data) (Unaudited) Three months ended Nine months ended December 31, December 31, 2005 2004 2005 2004 Product sales $17,246 $17,141 $51,510 $60,509 Healthcare services revenue 9,920 5,188 26,289 16,050 Total revenue 27,166 22,329 77,799 76,559 Cost and expenses Product sales costs 13,784 13,587 40,906 48,462 Healthcare services costs 9,151 6,751 24,559 16,798 Selling and marketing expenses 3,018 3,297 9,347 8,962 General and administrative expenses 1,729 2,039 5,743 5,190 Loss from operations (516) (3,345) (2,756) (2,853) Other (expenses) and income Interest expense (203) (36) (397) (108) Interest income 50 33 117 66 Foreign exchange gain (loss) 48 (20) 379 (50) Miscellaneous (expense) income - net (59) (31) 23 (65) Loss before income taxes (680) (3,399) (2,634) (3,010) Benefit from (provision for) income taxes 217 (314) 90 (549) Net loss $(463) $(3,713) $(2,544) $(3,559) Net loss per common share - basic and diluted $(.07) $(.69) $(.39) $(.68) Weighted average shares outstanding - basic and diluted 6,536,122 5,405,337 6,518,042 5,250,244 CHINDEX INTERNATIONAL, INC. CONSOLIDATED CONDENSED BALANCE SHEETS (thousands except share data) (Unaudited) December March 31, 31, 2005 2005 ASSETS Current assets: Cash and cash equivalents $7,683 $8,173 Trade accounts receivable, less allowance for doubtful accounts of $2,458 and $1,851, respectively Equipment sales receivables 11,491 13,120 Patient service receivables 4,532 2,706 Inventories, net 10,755 10,856 Deferred income tax 341 222 Other current assets 2,722 2,034 Total current assets 37,524 37,111 Property and equipment, net 18,064 17,620 Long-term deferred income taxes 2,210 1,780 Other assets 725 777 Total assets $58,523 $57,288 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable and accrued expenses $24,371 $26,420 Short-term portion of capitalized leases 82 189 Short-term debt and vendor financing 2,413 2,839 Income taxes payable 177 4 Total current liabilities 27,043 29,452 Long-term portion of capitalized leases 103 124 Long-term debt and vendor financing 8,802 2,749 Total liabilities 35,948 32,325 Stockholders' equity: Preferred stock, $.01 par value, 500,000 shares authorized, none issued 0 0 Common stock, $.01 par value, 13,600,000 shares authorized, including 1,600,000 designated Class B: Common stock - 5,783,515 and 5,728,443 shares issued and at December 31, 2005 and March 31, 2005, respectively 58 57 Class B stock - 775,000 shares issued and outstanding at December 31, 2005 and March 31, 2005 8 8 Additional paid in capital 35,995 35,884 Accumulated other comprehensive income 61 17 Accumulated deficit (13,547) (11,003) Total stockholders' equity 22,575 24,963 Total liabilities and stockholders' equity $58,523 $57,288 SEGMENT INFORMATION The Company has three reportable segments: Medical Capital Equipment, Healthcare Services and Healthcare Products Distribution. The Company evaluates performance and allocates resources based on profit or loss from operations before income taxes, not including gains or losses on the Company's investment portfolio. The following segment information has been provided per Statement of Financial Accounting Standards No. 131, "Disclosures about Segments of an Enterprise and Related Information:" Medical Healthcare Capital Healthcare Products Equipment Services Distribution Total As of December 31, 2005 Assets $23,310,000 $26,244,000 $8,969,000 $58,523,000 For the quarter ended December 31, 2005: Sales and service revenue $10,143,000 $9,920,000 $7,103,000 $27,166,000 Gross Profit 3,111,000 n/a 351,000 n/a Gross Profit % 31 % n/a 5 % n/a Income (loss) from operations $15,000 $439,000 $(970,000) $(516,000) Other (expense) net (164,000) Loss before income taxes $(680,000) Medical Healthcare Capital Healthcare Products Equipment Services Distribution Total As of March 31, 2005 Assets $22,698,000 $20,878,000 $13,712,000 $57,288,000 For the quarter ended December 31, 2004: Sales and service revenue $9,462,000 $5,188,000 $7,679,000 $22,329,000 Gross Profit 2,520,000 n/a 1,034,000 n/a Gross Profit % 27 % n/a 13 % n/a Loss from operations $(1,035,000) $(1,838,000) $(472,000) $(3,345,000) Other (expense) net (54,000) Loss before income taxes $(3,399,000) Medical Healthcare Capital Healthcare Products Equipment Services Distribution Total As of December 31, 2005 Assets $23,310,000 $26,244,000 $8,969,000 $58,523,000 For the nine-months ended December 31, 2005: Sales and service revenue $31,032,000 $26,289,000 $20,478,000 $77,799,000 Gross Profit 9,222,000 n/a 1,383,000 n/a Gross Profit % 30 % n/a 7 % n/a (Loss) income from operations $(241,000) $586,000 $(3,101,000) $(2,756,000) Other income net 122,000 Loss before income taxes $(2,634,000) Medical Healthcare Capital Healthcare Products Equipment Services Distribution Total As of March 31, 2005 Assets $22,698,000 $20,878,000 $13,712,000 $57,288,000 For the nine-months ended December 31, 2004: Sales and service revenue $34,393,000 $16,050,000 $26,116,000 $76,559,000 Gross Profit 9,220,000 n/a 2,826,000 n/a Gross Profit % 27 % n/a 11 % n/a Income (loss) from operations $90,000 $(1,446,000) $(1,497,000) $(2,853,000) Other (expense) net (157,000) Loss before income taxes $(3,010,000) For more information, please contact: Lawrence Pemble or Judy Zakreski Chindex International, Inc. Tel: +1-30-215-7777 SOURCE Chindex International, Inc.
沖データ、小型・低価格・高速印字を実現したBRICs市場向けドットインパクトプリンターを発売
沖データ、BRICs市場向けドットインパクトプリンタの戦略商品を新発売
~RoHS対応の小型・低価格商品を世界に先駆け中国市場に投入~
プリンティングソリューションの株式会社沖データ(社長:前野幹彦、本社:東京都港区)は、低価格でありながら高速印字と小型化を実現した、BRICs市場向けドットインパクトプリンタの新商品MICROLINE 1190の開発に成功しました。世界に先駆け今月より、成長を続ける中国市場に販売開始します。BRICs市場を主なターゲットとし、官公庁、金融機関、小売業などの企業ユーザに向けて、世界で2008年度20万台の販売を目指します。
新商品は、官公庁、金融、教育、小売、医療、輸送、自動車など幅広い業界の用途に活躍する、低価格ドットインパクトプリンタです。同価格帯のドットインパクトプリンタでは初めて、USBインターフェイスの標準装備と最大333CPSの高速印字を実現しました。また、様々な使用場所に対応できるよう、従来製品と比較して設置面積、容積、重量の20%削減に成功し、クラス最小サイズの設置面積と筐体容積を実現しています。なお、本商品はRoHSにも対応した高い環境性能を備えています。
世界のドットインパクトプリンタの市場は全体的には縮小傾向にあるものの、中国を中心としたアジア地域や中南米地域、東欧・中近東地域での低価格商品の需要が大きく、今後も堅調に推移すると予測されています。また、2006年度には380万台のドットインパクトプリンタ市場規模の中で、低価格商品市場は180万台あるとされており、新商品はこれらの市場の要求に応える機能と価格を備えています。
弊社のドットインパクトプリンタは、2005年に米国、西欧、日本総計で金額シェア1位になるなど、世界中の業務用プリンタユーザの高い信頼と支持を得ています。一方、これまでは高機能商品に注力してきたため、低価格商品の需要の高いBRICs市場では、2位にとどまっています。(注)
弊社では、BRICs市場特有の多様な要求に、きめ細かく応えることで、市場に最適化した商品をつくりあげることに成功しました。本商品は、世界最大のドットインパクトプリンタ市場である中国市場から販売を開始し、順次世界各地での展開を進めていきます。
(注)出典:IDC Worldwide Quarterly Hardcopy Peripherals Tracker, Q1 2006
ドットインパクトプリンタ:IDC定義によるシリアルドットマトリックスプリンタ
【 新製品の主な仕様 】
印字速度:最大333CPS
複写枚数:1+4
インターフェイス:セントロ、USB
サイズ:349(W)×232(D)×150(H)
※MICROLINEは、株式会社沖データの商標です。
※OKI Printing Solutionsは、株式会社沖データのブランドです。
※その他、記載されている会社名、製品名は各社の商標または登録商標です。
※沖データ中国向けホームページ:http://www.okidata.com.cn/
● 関連リンク
ソニー銀行、11月末まで住宅ローン金利優遇キャンペーンを実施
住宅ローン金利優遇キャンペーン実施のお知らせ
ソニー銀行株式会社(代表取締役社長:石井 茂/本社:東京都港区/通称:ソニーバンク)は、11月30日(木)まで、ソニーバンク標準の住宅ローン金利から一律0.9%(年利)の金利を優遇する住宅ローン金利優遇キャンペーンを行いますのでお知らせいたします。
キャンペーン期間中に仮審査お申し込みを受け付け、2007年3月30日(金)までにお借り入れの住宅ローンが対象となります。金利の優遇は、変動金利や固定金利〔2・3・5・7・10・15・20年、20年超(全期間)〕のすべての金利タイプについて、お借り入れ全期間に適用されます。金利タイプを変更された場合も、継続して優遇いたします。新規の住宅購入のほか、住宅ローンの借り換えにもご利用いただけます。
ソニーバンクの住宅ローンは、来店不要、保証料不要、インターネットで繰り上げ返済や金利タイプの変更が容易に可能など、インターネットの特性を活かした利便性の高い商品となっています。さらに、変動金利に固定金利を組み合わせる機能(部分固定金利特約)のご利用も可能です。
ソニーバンクは、お客さまの住宅資金ニーズに積極的にお応えするため、金利と利便性の両面から魅力のある住宅ローンを提供してまいります。
■住宅ローン金利優遇キャンペーンの概要
キャンペーン期間:2006年11月30日(木)まで
キャンペーン内容:キャンペーン期間中に仮審査お申し込みを受け付け、2007年3月30日(金)までにお借り入れの住宅ローン
キャンペーンの対象:住宅ローンのお借り入れ全期間、すべての金利タイプでソニーバンク標準の住宅ローン金利から一律0.9%(年利)を優遇
・キャンペーン期間中に、金融情勢等によっては本キャンペーンの優遇金利幅を変更する場合があります。
・すでにソニーバンクでお借り入れいただいている住宅ローンのお借り換えにはご利用いただけません。
・金融情勢等により、キャンペーン期間終了後も本キャンペーンのお取り扱いを継続する場合や、本キャンペーン内容を見直す場合があります。また今後予告なくお取り扱いを中止する場合があります。
・延滞が発生した場合は優遇を取り消し、金利を引き上げさせていただく場合があります。
以上
ソニーバンクのサイト
●企業サイト http://sonybank.net/
●サービスサイト
(インターネットバンキングサイト) http://moneykit.net/
(モバイルバンキングサイト) http://mb.moneykit.net/
(c)Sony Bank Inc. MONEYKit はソニー銀行株式会社の登録商標です。
お客さまからのお問い合わせ先
カスタマーセンター 0120-365-723(フリーダイヤル)
携帯電話・PHS・海外からは 03-6730-2700(通話料有料)
※番号をお間違えにならないようにくれぐれもご注意ください。
※IP電話をご利用の場合、ご入力内容が確認できないことがございます。
受け付け日:1月1日~3日および5月3日~5日を除く毎日
受け付け時間:
平日 9:00~20:00
土・日・祝日 9:00~17:00(12月31日9:00~17:00)
● 関連リンク
明星食品、スープの旨みをアップしたカップめん「明星 中華そば いろは屋の塩」を発売
オーソドックス味覚で充実した品質、リーズナブルなカップ麺。深みのある旨味がアップして登場!
『明星 中華そば いろは屋の塩』
リニューアル発売
明星食品株式会社(社長:永野博信)では、カップめんの『明星 中華そば いろは屋の塩』を、2006年 9月19日(火)から全国でリニューアル発売いたします。
今回の商品は、"オーソドックス味覚で充実した品質、しかもリーズナブルなカップ麺"をコンセプトにしています。
今回のリニューアルはスープを中心に行い、オホーツク産100%のほたて貝柱粉末を使用し、深みのある旨味がアップしました。
商品の概要は次の通りです。
■商品の概要
商 品 名:明星 中華そば いろは屋の塩
内 容 量:94g(めん 70g)
荷 姿:94g×12入=1ケース
価 格:希望小売価格 155円(税抜き)
JANコード :4902881409551
発売日及び発売地区:2006年9月19日(火)より、全国でリニューアル発売
■商品の特長
●め ん:しなやかで歯切れのよさが特長の食べやすい中太麺です。(スーパーノンフライめん)
●ス ー プ:鶏がらをベースに野菜の旨みを加えた、やさしい風味の塩味スープ。粉末スープにオホーツク産100%のほたて貝柱粉末を使用し、コクと深みのある塩味に改良しました。
●か や く:食感が良く、ジューシーな角型のフリーズドライの焼豚、歯ごたえの良いメンマ、ねぎのかやくです。
●あとのせかやく:あざやかな彩りの白髪ねぎと粗挽き胡麻中心のスパイスミックスです。
●パッケージ:ネーミングの「いろは屋」には、基本、定番、初心、素朴などの意味あいを込め、まじめで誠実な中華そば屋の世界観を演出しています。暖簾をモチーフにした基本デザインを踏襲し、改良ポイントである"ホタテの旨み"をわかりやすくアピールできるようなラベル風のデザインにしました。
●読者のお問い合わせ先
明星食品株式会社 お客様サービス室 03-3470-1311